Risk of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from three randomized clinical trials involving first-line atezolizumab treatment.

Authors

Yue Zhou

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Yue Zhou , JianJiao Ni , Zhengfei Zhu , Zhen Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) with brain metastases treated with pembrolizumab-based therapy.

First Author: Lova Sun

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.

First Author: Li Zhang

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).

First Author: Melina Elpi Marmarelis

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.

First Author: Luis G. Paz-Ares